PGI13 COST PER RESPONDER ANALYSIS EVALUATED THROUGH CLINICAL RESPONSE AND REMISSION RATE OF ADALIMUMAB, USTEKINUMAB AND VEDOLIZUMAB FOR THE TREATMENT OF CROHN'S DISEASE FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

Nov 1, 2019, 00:00 AM
10.1016/j.jval.2019.09.1136
https://www.valueinhealthjournal.com/article/S1098-3015(19)33514-4/fulltext
Section Title :
Section Order : 10996
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33514-4&doi=10.1016/j.jval.2019.09.1136
HEOR Topics :
Tags :
Regions :